Surveillance prostate biopsy utilizing piflufolastat F 18-PET/CT targeting in the intact prostate – A case report

75-year-old patient with cochlear implant diagnosed with very low risk prostate cancer (PSA 6.44 ng/mL, and Grade Group 1 (left apical core)) managed on Active Surveillance (AS). After four years monitoring on AS, PSA was observed to increase to 10.84 and patient was reevaluated for disease progress...

Descripción completa

Detalles Bibliográficos
Autores principales: Grossman, Tim, Morton, Kathryn A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9970888/
https://www.ncbi.nlm.nih.gov/pubmed/36866336
http://dx.doi.org/10.1016/j.eucr.2023.102352
Descripción
Sumario:75-year-old patient with cochlear implant diagnosed with very low risk prostate cancer (PSA 6.44 ng/mL, and Grade Group 1 (left apical core)) managed on Active Surveillance (AS). After four years monitoring on AS, PSA was observed to increase to 10.84 and patient was reevaluated for disease progression. Due to cochlear implant, multiparametric MRI was not an imaging option and patient was referred for piflufolastat F 18-PET/CT. In addition to previously identified left sided lesion, tracer uptake was observed within the posterior transition and peripheral zone of the right lobe of the prostate, which ultimately confirmed disease progression on targeted biopsy.

Ejemplares similares